StockUS listing USGDTCNASDAQHealthcareEarnings Deterioration

CytoMed Therapeutics Limited Ordinary Shares(GDTC) Stock Analysis | Healthcare

USD --+0.00%
Reward35Moderate
Risk32Moderate
75%Data
Revenue down 16% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 9.01M
Reward Ratingⓘ35 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ32 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GDTC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CytoMed Therapeutics Limited Ordinary Shares?

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

AI Brief Pro

The brief on CytoMed Therapeutics Limited Ordinary Shares

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CytoMed Therapeutics Limited Ordinary Shares?

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 9.01M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (35)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.024
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.